

# Salvatore Siena

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3679437/salvatore-siena-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

350  
papers

46,356  
citations

86  
h-index

213  
g-index

395  
ext. papers

53,177  
ext. citations

7.4  
avg, IF

6.96  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 350 | The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102351  | 14.4 | 3         |
| 349 | Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 127-127                                      | 2.2  |           |
| 348 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with Fusion-Positive Solid Tumors.. <i>Clinical Cancer Research</i> , <b>2022</b> ,   | 12.9 | 10        |
| 347 | Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.. <i>ESMO Open</i> , <b>2022</b> , 7, 100404  | 6    | 7         |
| 346 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , <b>2022</b> , 100332  | 1.4  | 0         |
| 345 | Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , <b>2021</b> , 24, 897-912  | 7.6  | 1         |
| 344 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1253-1263                       | 2.2  | 22        |
| 343 | Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. <i>Nature Communications</i> , <b>2021</b> , 12, 2340   | 17.4 | 6         |
| 342 | Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 811-824  | 5.4  | 2         |
| 341 | Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1923-1937                 | 24.4 | 10        |
| 340 | Precision oncology in metastatic colorectal cancer - from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 506-525  | 19.4 | 27        |
| 339 | Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3506-3506 | 2.2  | 21        |
| 338 | Clonally expanded EOMES Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , <b>2021</b> , 22, 735-745   | 19.1 | 10        |
| 337 | Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6  | 3         |
| 336 | Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 779-789                                | 21.7 | 53        |
| 335 | Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6  | 6         |
| 334 | Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,   | 3.6  | 1         |

|     |   |      |     |
|-----|---|------|-----|
| 333 | Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases. <i>Archives of Public Health</i> , <b>2021</b> , 79, 12   | 2.6  |     |
| 332 | The Evolutionary Landscape of Treatment for Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6  | 12  |
| 331 | Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3126-3140  | 12.9 | 6   |
| 330 | Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , <b>2021</b> , 15, 32                 | 1.2  | 1   |
| 329 | Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , <b>2021</b> , 16, 309-324   | 5    | 2   |
| 328 | Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged $\geq 75$ Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e567-e571                              | 4.9  | 10  |
| 327 | A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1774-1783 | 4.3  | 4   |
| 326 | EGFR Blockade Reverts Resistance to KRAS Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1129-1139   | 24.4 | 100 |
| 325 | The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 533   | 5.3  | 11  |
| 324 | Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. <i>JAMA Oncology</i> , <b>2020</b> , 6, 927-929   | 13.4 | 9   |
| 323 | Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 21  |
| 322 | Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 333-341  | 3.5  | 16  |
| 321 | Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 256-262.e2  | 3.8  | 22  |
| 320 | -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2466-2476                      | 12.9 | 19  |
| 319 | Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 102020  | 14.4 | 4   |
| 318 | Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. <i>European Radiology Experimental</i> , <b>2020</b> , 4, 62  | 4.5  | 14  |
| 317 | A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4000-4000            | 2.2  | 37  |
| 316 | The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4124-TPS4124   | 2.2  | 6   |

|     |   |      |     |
|-----|---|------|-----|
| 315 | Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 511-511 | 2.2  | 6   |
| 314 | Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. <i>ESMO Open</i> , <b>2020</b> , 5, e000860  | 6    | 1   |
| 313 | A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1372-1384  | 12.9 | 38  |
| 312 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 261-270  | 21.7 | 154 |
| 311 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 271-282  | 21.7 | 454 |
| 310 | Breaking Barriers in HER2+ Cancers. <i>Cancer Cell</i> , <b>2020</b> , 38, 317-319  | 24.3 | 3   |
| 309 | Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , <b>2020</b> , 5, e000911   | 6    | 35  |
| 308 | A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5102-5112   | 12.9 | 7   |
| 307 | Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 91, 102112  | 14.4 | 8   |
| 306 | Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3215-3223   | 7.5  | 7   |
| 305 | CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3  | 14  |
| 304 | Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 79, 101893  | 14.4 | 17  |
| 303 | A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , <b>2019</b> , 79, 5884-5896   | 10.1 | 26  |
| 302 | Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. <i>Cancer Epidemiology</i> , <b>2019</b> , 60, 134-140   | 2.8  | 24  |
| 301 | A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 91-101.e3   | 3.8  | 15  |
| 300 | Combined Low Densities of FoxP3 and CD3 Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 751-758  | 12.5 | 19  |
| 299 | Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , <b>2019</b> , 123, 98-105  | 5.6  | 48  |
| 298 | The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1510-1511  | 13.4 | 0   |

|     |  |      |     |
|-----|--|------|-----|
| 297 | Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6243-6259   | 12.9 | 25  |
| 296 | A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 121-130   | 7.5  | 29  |
| 295 | High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 622                            | 5.3  | 17  |
| 294 | Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). <i>Annals of Oncology</i> , <b>2019</b> , 30, iv134             | 10.3 | 6   |
| 293 | Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , <b>2019</b> , 366, 1473-1480   | 9.3  | 148 |
| 292 | Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 <b>2019</b> ,                                |      | 3   |
| 291 | Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3017-3017      | 17   |     |
| 290 | Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS2659-TPS2659      | 2.2  | 8   |
| 289 | Mutational signatures of early-onset colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15113-e15113   | 15.1 | 13  |
| 288 | Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15086-e15086                                 | 2.2  |     |
| 287 | Plasma HER2 () Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3046-3053   | 12.9 | 58  |
| 286 | HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 1395-1402  | 5.7  | 45  |
| 285 | Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , <b>2019</b> , 4,  | 6    | 12  |
| 284 | Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 73, 41-53   | 14.4 | 44  |
| 283 | A Multicenter Phase II Study of AMG 337 in Patients with -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other -Amplified Solid Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2414-2423 | 12.9 | 37  |
| 282 | Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , <b>2019</b> , 13, 109-131  | 7.9  | 173 |
| 281 | Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , <b>2018</b> , 249, 145-159                          | 3.2  | 1   |
| 280 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1108-1119   | 10.3 | 101 |

|     |  |      |     |
|-----|--|------|-----|
| 279 | Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , <b>2018</b> , 8, 428-443   | 24.4 | 296 |
| 278 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , <b>2018</b> , 3, e000299   | 6    | 24  |
| 277 | Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e175245  | 13.4 | 54  |
| 276 | The subgroups of the phase III RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 90, 63-72   | 7.5  | 48  |
| 275 | Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 170-178.e3                                   | 3.8  | 31  |
| 274 | Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 114-116   | 2.2  | 1   |
| 273 | Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , <b>2018</b> , 4, 19-20  | 13.4 | 14  |
| 272 | Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 119-126  | 10.3 | 46  |
| 271 | Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 321-335                | 4.9  | 19  |
| 270 | Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kline Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 50-57.e8   | 3.8  | 5   |
| 269 | Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 2143-2146   | 4.3  | 6   |
| 268 | Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , <b>2018</b> , 34, 148-162.e7   | 24.3 | 77  |
| 267 | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 303-312 | 8.7  | 17  |
| 266 | Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , <b>2018</b> , 9, 2287  | 17.4 | 14  |
| 265 | Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , <b>2018</b> , 67, 1995-2005   | 19.2 | 119 |
| 264 | Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 581-581  | 2.2  | 1   |
| 263 | Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 80-83  | 3.8  | 34  |
| 262 | OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S321-S322  | 8.9  | 34  |



|     |  |      |     |
|-----|--|------|-----|
| 261 | Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. <i>ESMO Open</i> , <b>2018</b> , 3, e000353   | 6    | 30  |
| 260 | TRKA expression and gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 926-931  | 3.9  | 9   |
| 259 | Exploring the links between cancer and placenta development. <i>Open Biology</i> , <b>2018</b> , 8,  | 7    | 52  |
| 258 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3657-3666 <sup>12.9</sup>   | 12.9 | 44  |
| 257 | Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, e153-e163  | 3.8  | 70  |
| 256 | Integrating liquid biopsies into the management of cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 531-548   | 19.4 | 970 |
| 255 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , <b>2017</b> , 7, 400-409   | 24.4 | 475 |
| 254 | Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1862-1868  | 10.3 | 126 |
| 253 | ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,   | 9.7  | 126 |
| 252 | Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1302-1308   | 10.3 | 23  |
| 251 | Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 43-50  | 7.5  | 22  |
| 250 | Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , <b>2017</b> , 552, 116-120  | 50.4 | 290 |
| 249 | Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , <b>2017</b> , 12, 525-533             | 5    | 11  |
| 248 | OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1783  | 8.9  | 16  |
| 247 | Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. <i>Annals of Oncology</i> , <b>2017</b> , 28, iii113-iii114   | 10.3 | 2   |
| 246 | Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer <b>2017</b> ,  |      | 16  |
| 245 | A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9518-9518 | 2.2  | 18  |
| 244 | Identification and characterization of a novel rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , <b>2017</b> , 8, 55353-55360  | 3.3  | 23  |

|     |   |      |     |
|-----|---|------|-----|
| 243 | Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 589-589   | 2.2  |     |
| 242 | Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 158-62   | 2.3  | 22  |
| 241 | Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 51, 54-62   | 14.4 | 19  |
| 240 | Quality of life during first-line FOLFOX4+panitumumab in wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. <i>ESMO Open</i> , <b>2016</b> , 1, e000041   | 6    | 13  |
| 239 | Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4504-15  | 10.1 | 63  |
| 238 | Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e54-6  | 2.2  | 9   |
| 237 | Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , <b>2016</b> , 27, 648-53           | 10.3 | 29  |
| 236 | Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, 213-21  | 3.8  | 23  |
| 235 | Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1062-1067  | 10.3 | 28  |
| 234 | Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 147-153   | 24.4 | 255 |
| 233 | Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 36-44   | 24.4 | 200 |
| 232 | Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,   | 9.7  | 94  |
| 231 | Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1649-54   | 3.9  | 16  |
| 230 | Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results <b>2016</b> ,   |      | 14  |
| 229 | Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial <b>2016</b> ,   |      | 3   |
| 228 | HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS774-TPS774 | 2.2  | 16  |
| 227 | Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS11615-TPS11615   | 2.2  | 15  |
| 226 | The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS3636-TPS3636   | 2.2  |     |



|     |   |      |     |
|-----|---|------|-----|
| 225 | Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4345-4353  | 2.3  | 49  |
| 224 | Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). <i>Cancer</i> , <b>2016</b> , 122, 574-81  | 6.4  | 96  |
| 223 | gene fusions as novel targets of cancer therapy across multiple tumour types. <i>ESMO Open</i> , <b>2016</b> , 1, e000023   | 0.0  | 289 |
| 222 | Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). <i>ESMO Open</i> , <b>2016</b> , 1, e000111                                    | 6    | 22  |
| 221 | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 13665  | 17.4 | 121 |
| 220 | Clonal evolution and -coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. <i>ESMO Open</i> , <b>2016</b> , 1, e000079   | 6    | 2   |
| 219 | Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials. <i>Quality of Life Research</i> , <b>2016</b> , 25, 2645-2656   | 3.7  | 11  |
| 218 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 738-746      | 21.7 | 533 |
| 217 | Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 937-48 | 21.7 | 240 |
| 216 | BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2092-7   | 10.3 | 110 |
| 215 | Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1994-1999  | 18.3 | 93  |
| 214 | Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1231-42   | 7.5  | 53  |
| 213 | The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. <i>Nature Communications</i> , <b>2015</b> , 6, 7002  | 17.4 | 178 |
| 212 | The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , <b>2015</b> , 526, 263-7   | 50.4 | 310 |
| 211 | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , <b>2015</b> , 28, 1481-91   | 9.8  | 144 |
| 210 | High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , <b>2015</b> , 26, 167-172                                   | 10.3 | 15  |
| 209 | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , <b>2015</b> , 21, 795-801   | 50.5 | 557 |
| 208 | Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1730-4  | 8.7  | 57  |

|     |   |      |     |
|-----|---|------|-----|
| 207 | nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,   | 9.7  | 368 |
| 206 | Alka-372-001: First-in-human, phase I study of entrectinib [an oral pan-trk, ROS1, and ALK inhibitor] in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2517-2517  | 2.2  | 20  |
| 205 | Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3508-3508  | 2.2  | 23  |
| 204 | Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3558-3558  | 2.2  | 15  |
| 203 | A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 281-281  | 2.2  | 2   |
| 202 | Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 565-565   | 2.2  | 2   |
| 201 | Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 583-583   | 2.2  | 1   |
| 200 | GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (WT) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 281-281 | 2.2  | 10  |
| 199 | Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 693-693  | 2.2  | 2   |
| 198 | Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , <b>2015</b> , 6, 31604-12  | 3.3  | 27  |
| 197 | Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e22075-e22075   | 2.2  |     |
| 196 | Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1346-1355  | 10.3 | 353 |
| 195 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2014</b> , 384, 319-28   | 4.0  | 933 |
| 194 | The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1495-507   | 7.9  | 101 |
| 193 | Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt322  | 9.7  | 58  |
| 192 | Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1269-80  | 24.4 | 326 |
| 191 | Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1783-93   | 4.9  | 7   |
| 190 | Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 255-65  | 3.5  | 16  |

|     |   |      |      |
|-----|---|------|------|
| 189 | Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra24  | 17.5 | 2741 |
| 188 | Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra26   | 17.5 | 203  |
| 187 | Acquired resistance to EGFR-targeted therapies in colorectal cancer. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1084-94   | 9.9  | 94   |
| 186 | Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 182-6   | 3.3  | 34   |
| 185 | Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2502-2502  | 2.2  | 17   |
| 184 | Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients' avatars.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2626-2626  | 2.2  | 3    |
| 183 | Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3550-3550  | 2.2  | 3    |
| 182 | Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01100100).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1001-1001             | 2.2  | 31   |
| 181 | Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6060-6060   | 2.2  | 11   |
| 180 | Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6061-6061  | 2.2  | 6    |
| 179 | Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14560-e14560   | 2.2  | 1    |
| 178 | Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 178-178  | 2.2  | 12   |
| 177 | Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 251-251 | 2.2  | 3    |
| 176 | Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 551-551   | 2.2  | 1    |
| 175 | Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4027-4027                              | 2.2  | 1    |
| 174 | Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3557-3557   | 2.2  |      |
| 173 | Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14613-e14613   | 2.2  | 1    |
| 172 | KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1259-65   | 7.5  | 141  |

|     |   |      |      |
|-----|---|------|------|
| 171 | Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , <b>2013</b> , 381, 1537  | 40   | 14   |
| 170 | Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. <i>Cancer</i> , <b>2013</b> , 119, 3429-35  | 6.4  | 23   |
| 169 | An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. <i>Targeted Oncology</i> , <b>2013</b> , 8, 127-36       | 5    | 25   |
| 168 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2013</b> , 381, 303-12   | 40   | 1783 |
| 167 | Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1902-12  | 12.9 | 192  |
| 166 | Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 759-65  | 2.2  | 189  |
| 165 | Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. <i>Clinical Colorectal Cancer</i> , <b>2013</b> , 12, 45-53 <sup>3,8</sup>                                     |      | 12   |
| 164 | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discovery</i> , <b>2013</b> , 3, 658-73  | 24.4 | 489  |
| 163 | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1023-34   | 59.2 | 1645 |
| 162 | Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2265-72  | 12.9 | 85   |
| 161 | Overall Survival (OS) and Tumour Shrinkage Outcomes in Patients with Symptomatic/Asymptomatic Metastatic Colorectal Cancer (mCRC): Data From the Prime Study. <i>Annals of Oncology</i> , <b>2013</b> , 24, iv32  | 10.3 | 3    |
| 160 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e62264  | 3.7  | 18   |
| 159 | Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e80437   | 3.7  | 24   |
| 158 | Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3617-3617 | 2.2  | 28   |
| 157 | Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3636-3636  | 2.2  | 14   |
| 156 | Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS3648-TPS3648                      | 2.2  | 7    |
| 155 | Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4-4   | 2.2  | 39   |
| 154 | Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 381-381  | 2.2  | 2    |

|     |   |      |      |
|-----|---|------|------|
| 153 | Time course of regorafenib-associated adverse events in the phase III CORRECT study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 467-467   | 2.2  | 14   |
| 152 | Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. <i>Annals of Translational Medicine</i> , <b>2013</b> , 1, 12  | 3.2  | 4    |
| 151 | Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11005-11005   | 2.2  | 0    |
| 150 | Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11058-11058   | 2.2  |      |
| 149 | Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1830-1844  | 8.9  | 17   |
| 148 | Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. <i>Cytotherapy</i> , <b>2012</b> , 14, 80-90  | 4.8  | 23   |
| 147 | Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3082-92  | 7.5  | 404  |
| 146 | First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3002-11   | 2.2  | 193  |
| 145 | Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. <i>BMC Cancer</i> , <b>2012</b> , 12, 158   | 4.8  | 11   |
| 144 | Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , <b>2012</b> , 8, 272-276   | 1    | 1    |
| 143 | Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1185-1189   | 10.3 | 44   |
| 142 | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , <b>2012</b> , 486, 532-6   | 50.4 | 1327 |
| 141 | T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , <b>2012</b> , 23, 435-41  | 10.3 | 42   |
| 140 | Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 218-23  | 3.9  | 29   |
| 139 | Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1823-1829  | 8.9  | 217  |
| 138 | Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase III trial (NCT01001002). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5510-5510 | 2.2  | 3    |
| 137 | Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7550-7550   | 2.2  | 3    |
| 136 | The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS3637-TPS3637  | 2.2  | 3    |



|     |   |      |      |
|-----|---|------|------|
| 135 | Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 383-383   | 2.2  | 8    |
| 134 | Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 531-531  | 2.2  | 4    |
| 133 | Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA385-LBA385 | 2.2  | 25   |
| 132 | Targeted therapies: how personal should we go?. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 9, 87-97  | 19.4 | 87   |
| 131 | Cardiotoxicity of novel molecular targeted therapies of cancer. <i>Journal of Cardiovascular Echography</i> , <b>2011</b> , 21, 78-85   | 0.6  |      |
| 130 | A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 508-23  | 24.4 | 668  |
| 129 | No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1614-1621   | 10.3 | 36   |
| 128 | KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. <i>PLoS ONE</i> , <b>2011</b> , 6, e29146   | 3.7  | 26   |
| 127 | Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1812-20   | 27.4 | 580  |
| 126 | Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 573-575   | 9.7  | 0    |
| 125 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. <i>Annals of Oncology</i> , <b>2010</b> , 21, 655-661   | 10.3 | 72   |
| 124 | Reply to E. Hawkes et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e532-e533   | 2.2  | 1    |
| 123 | Malignant peritoneal mesothelioma: a multicenter study on 81 cases. <i>Annals of Oncology</i> , <b>2010</b> , 21, 348-353   | 10.3 | 81   |
| 122 | Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4697-705                                       | 2.2  | 1405 |
| 121 | Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1254-61   | 2.2  | 582  |
| 120 | Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 3, S1-5   | 14.4 | 32   |
| 119 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , <b>2010</b> , 11, 753-62  | 21.7 | 1653 |
| 118 | Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <i>Targeted Oncology</i> , <b>2010</b> , 5, 19-28  | 5    | 26   |



|     |   |      |      |
|-----|---|------|------|
| 117 | Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. <i>Cancer</i> , <b>2010</b> , 116, 1827-37            | 6.4  | 42   |
| 116 | Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyond ERAS that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC) <b>2010</b> , |      | 6    |
| 115 | Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. <i>Current Opinion in Molecular Therapeutics</i> , <b>2010</b> , 12, 703-11  |      |      |
| 114 | Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. <i>PLoS ONE</i> , <b>2009</b> , 4, e7287  | 3.7  | 209  |
| 113 | Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. <i>Cancer</i> , <b>2009</b> , 115, 1544-54                                | 6.4  | 114  |
| 112 | Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. <i>Cancer</i> , <b>2009</b> , 115, 1169-73  | 6.4  | 10   |
| 111 | Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 52, 767-71  | 3    | 124  |
| 110 | Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). <i>British Journal of Cancer</i> , <b>2009</b> , 101, 1261-8     | 8.7  | 121  |
| 109 | Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. <i>Lung Cancer</i> , <b>2009</b> , 64, 211-8   | 5.9  | 98   |
| 108 | An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <i>Lung Cancer</i> , <b>2009</b> , 64, 199-206  | 5.9  | 19   |
| 107 | PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Research</i> , <b>2009</b> , 69, 1851-7   | 10.1 | 642  |
| 106 | Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1308-24   | 9.7  | 424  |
| 105 | Imaging in nasopharyngeal carcinoma: the value of 18-Fluorine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI. <i>Radiology and Oncology</i> , <b>2009</b> , 43,  | 3.8  | 1    |
| 104 | Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 616-24  | 2.4  | 34   |
| 103 | Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 42, 131-3  | 4.4  | 3    |
| 102 | Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology</i> , <b>2008</b> , 9, 39-44                      | 21.7 | 114  |
| 101 | EGFR FISH in colorectal cancer: what is the current reality?. <i>Lancet Oncology</i> , <b>2008</b> , 9, 402-3   | 21.7 | 38   |
| 100 | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1626-34  | 2.2  | 2666 |

|    |   |      |      |
|----|---|------|------|
| 99 | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5705-12  | 2.2  | 1358 |
| 98 | Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4217-9   | 2.2  | 191  |
| 97 | First-line single-agent cetuximab in patients with advanced colorectal cancer. <i>Annals of Oncology</i> , <b>2008</b> , 19, 711-6  | 10.3 | 34   |
| 96 | Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5335-43  | 2.2  | 88   |
| 95 | Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia. <i>Chemotherapy</i> , <b>2008</b> , 54, 417-20  | 3.2  | 3    |
| 94 | Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1619-25                           | 2.2  | 131  |
| 93 | A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1888-93  | 10.3 | 37   |
| 92 | An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. <i>Annals of Oncology</i> , <b>2008</b> , 19, 92-8                                  | 10.3 | 131  |
| 91 | Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. <i>Targeted Oncology</i> , <b>2008</b> , 3, 127-130 | 5    | 4    |
| 90 | Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. <i>Anticancer Research</i> , <b>2008</b> , 28, 1813-20   | 2.3  | 3    |
| 89 | Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. <i>Anticancer Research</i> , <b>2008</b> , 28, 3991-2   | 2.3  |      |
| 88 | Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1658-64 | 2.2  | 1611 |
| 87 | GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. <i>Cytotherapy</i> , <b>2007</b> , 9, 499-507   | 4.8  | 15   |
| 86 | Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2007</b> , 92, 418-20                       | 6.6  | 13   |
| 85 | Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. <i>European Urology</i> , <b>2007</b> , 52, 134-41      | 10.2 | 211  |
| 84 | Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. <i>Supportive Care in Cancer</i> , <b>2007</b> , 15, 1057-66                                  | 3.9  | 11   |
| 83 | Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 1469-74  | 8.7  | 64   |
| 82 | Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. <i>Current Cancer Therapy Reviews</i> , <b>2007</b> , 3, 249-254   | 0.4  |      |

|    |  |      |     |
|----|--|------|-----|
| 81 | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). <i>Annals of Oncology</i> , <b>2007</b> , 18, 510-7  | 10.3 | 235 |
| 80 | Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3238-45   | 2.2  | 293 |
| 79 | Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. <i>Cancer Research</i> , <b>2007</b> , 67, 2643-8   | 10.1 | 708 |
| 78 | Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion. <i>Anticancer Research</i> , <b>2007</b> , 27, 3273-8   | 2.3  | 7   |
| 77 | Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. <i>Future Oncology</i> , <b>2006</b> , 2, 667-76  | 3.6  | 1   |
| 76 | Cetuximab for treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 7, vii66-7   | 10.3 | 9   |
| 75 | Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 2, ii49-51  | 10.3 | 4   |
| 74 | Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1134-40  | 10.3 | 72  |
| 73 | High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1479-88  | 10.3 | 34  |
| 72 | Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. <i>Haematologica</i> , <b>2006</b> , 91, 1635-43   | 6.6  | 29  |
| 71 | Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. <i>Lancet Oncology</i> , <b>2005</b> , 6, 279-86  | 21.7 | 833 |
| 70 | Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2005</b> , 11, 423-8 | 4.7  | 3   |
| 69 | Survival of adults treated for medulloblastoma using paediatric protocols. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1304-10   | 7.5  | 49  |
| 68 | Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , <b>2005</b> , 104, 2099-103   | 6.4  | 49  |
| 67 | Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma. <i>Current Gene Therapy</i> , <b>2005</b> , 5, 511-21   | 4.3  | 5   |
| 66 | HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. <i>Oncologist</i> , <b>2005</b> , 10, 345-56  | 5.7  | 232 |
| 65 | Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8942-9  | 2.2  | 218 |
| 64 | Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1848-9  | 10.3 | 23  |

|    |  |      |      |
|----|--|------|------|
| 63 | Treatment of metastatic neuroendocrine carcinomas based on WHO classification. <i>Anticancer Research</i> , <b>2005</b> , 25, 4463-9   | 2.3  | 26   |
| 62 | Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2004</b> , 15, 113-7                        | 10.3 | 63   |
| 61 | Iron supplement in cancer patients receiving erythropoietin. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4428; author reply 4428-9   | 2.2  | 1    |
| 60 | Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 34, 917-8  | 4.4  | 0    |
| 59 | Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. <i>International Journal of Cancer</i> , <b>2004</b> , 110, 76-86  | 7.5  | 19   |
| 58 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 337-45  | 59.2 | 4112 |
| 57 | Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1177-84  | 10.3 | 19   |
| 56 | Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study. <i>Journal of Chemotherapy</i> , <b>2003</b> , 15, 394-9 | 2.3  | 6    |
| 55 | Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. <i>Blood</i> , <b>2003</b> , 102, 3043-51   | 2.2  | 44   |
| 54 | Absence of c-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer. <i>Cancer</i> , <b>2003</b> , 97, 2926-7; author reply 2927-8  | 6.4  |      |
| 53 | Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 48, S39-47  | 7    | 18   |
| 52 | Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 32, 489-94                            | 4.4  | 44   |
| 51 | A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. <i>Annals of Oncology</i> , <b>2003</b> , 14, 29-35   | 10.3 | 443  |
| 50 | A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. <i>Oncology Reports</i> , <b>2003</b> , 10, 715-24  | 3.5  | 74   |
| 49 | Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. <i>Cancer</i> , <b>2002</b> , 94, 2409-15   | 6.4  | 99   |
| 48 | Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). <i>Annals of Oncology</i> , <b>2002</b> , 13, 716-20                                    | 10.3 | 41   |
| 47 | Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1211-20   | 9.7  | 390  |
| 46 | Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen <b>2002</b> , 94, 2409   |      | 5    |

|    |  |      |     |
|----|--|------|-----|
| 45 | Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies. / <i>Supplementi Di Tumori</i> , <b>2002</b> , 1, S46-8  |      |     |
| 44 | H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). <i>Blood</i> , <b>2001</b> , 97, 3910-8        | 2.2  | 114 |
| 43 | Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. <i>British Journal of Haematology</i> , <b>2000</b> , 108, 653-9                          | 4.5  | 21  |
| 42 | The effect of anticonvulsant drugs on blood levels of methotrexate. <i>Journal of Neuro-Oncology</i> , <b>2000</b> , 48, 249-50  | 4.8  | 14  |
| 41 | Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3319-20  | 2.2  | 16  |
| 40 | Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1360-77  | 2.2  | 265 |
| 39 | Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1271-2  | 9.7  | 2   |
| 38 | Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. <i>Transfusion</i> , <b>1999</b> , 39, 48-55  | 2.9  | 41  |
| 37 | Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF. <i>Best Practice and Research in Clinical Haematology</i> , <b>1999</b> , 12, 27-39  | 4.2  | 8   |
| 36 | Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. <i>Gene Therapy</i> , <b>1998</b> , 5, 465-72   |      | 37  |
| 35 | A Case of Metastatic Axillary Lymph Nodes Involvement from Unknown Primary Cancer: Clinical Usefulness of [99mTc]-Sestamibi. <i>Tumori</i> , <b>1998</b> , 84, 612-613   | 1.7  | 2   |
| 34 | High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1290-7  | 59.2 | 410 |
| 33 | Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 2312-21 | 2.2  | 150 |
| 32 | Expansion of Immunostimulatory Dendritic Cells from Peripheral Blood of Patients with Cancer. <i>Oncologist</i> , <b>1997</b> , 2, 65-69   | 5.7  | 5   |
| 31 | Long-term hematopoietic culture-initiating cells are more abundant in mobilized peripheral blood grafts than in bone marrow but have a more limited ex vivo expansion potential. <i>Blood Cells, Molecules, and Diseases</i> , <b>1996</b> , 22, 68-81 | 2.1  | 21  |
| 30 | Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 628-35                      | 2.2  | 27  |
| 29 | Combined negative and positive selection of mobilized CD34 blood cells. <i>British Journal of Haematology</i> , <b>1996</b> , 94, 716-21   | 4.5  | 11  |
| 28 | High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>1994</b> , 12, 503-9   | 2.2  | 65  |



|    |  |      |     |
|----|--|------|-----|
| 27 | Clinical utilisation of human haematopoietic progenitors elicited in peripheral blood by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 235-8  | 7.5  | 6   |
| 26 | Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. <i>Annals of Oncology</i> , <b>1994</b> , 5, 935-41  | 10.3 | 39  |
| 25 | Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). <i>Stem Cells</i> , <b>1993</b> , 11 Suppl 2, 72-5   | 5.8  | 3   |
| 24 | High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update. <i>Annals of Oncology</i> , <b>1993</b> , 4, 889-91   | 10.3 | 53  |
| 23 | Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m <sup>2</sup> ) cyclophosphamide cancer therapy. <i>Annals of Oncology</i> , <b>1993</b> , 4, 759-66   | 10.3 | 15  |
| 22 | Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. <i>Journal of Clinical Oncology</i> , <b>1992</b> , 10, 1955-62           | 2.2  | 43  |
| 21 | Practical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients. <i>International Journal of Cell Cloning</i> , <b>1992</b> , 10, 26-29   |      | 4   |
| 20 | Hematopoietic stem cell transplantation in the treatment of lymphoma. <i>Current Opinion in Oncology</i> , <b>1991</b> , 3, 838-42   | 4.2  |     |
| 19 | Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. <i>British Journal of Haematology</i> , <b>1991</b> , 78, 197-205  | 4.5  | 24  |
| 18 | Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. <i>Annals of Oncology</i> , <b>1991</b> , 2 Suppl 1, 9-16   | 10.3 | 59  |
| 17 | Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1991</b> , 27, 22-7   |      | 46  |
| 16 | Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1991</b> , 27, 561-5   |      | 27  |
| 15 | Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. <i>Annals of Oncology</i> , <b>1991</b> , 2, 645-53   | 10.3 | 50  |
| 14 | Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1990</b> , 19, 743-9       | 4    | 12  |
| 13 | Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>1990</b> , 8, 768-78 | 2.2  | 160 |
| 12 | Total body irradiation and high-dose melphalan with bone marrow transplantation at Istituto Nazionale Tumori, Milan, Italy. <i>Radiotherapy and Oncology</i> , <b>1990</b> , 18 Suppl 1, 105-9   | 5.3  | 4   |
| 11 | Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1990</b> , 26, 562-4  |      | 46  |
| 10 | Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. <i>Journal of Clinical Oncology</i> , <b>1989</b> , 7, 338-43   | 2.2  | 33  |



|   |  |      |     |
|---|--|------|-----|
| 9 | Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?. <i>Hematological Oncology</i> , <b>1989</b> , 7, 139-48 | 1.3  | 99  |
| 8 | Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. <i>Lancet, The</i> , <b>1989</b> , 2, 580-5   | 4.0  | 533 |
| 7 | Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation. <i>Transplantation</i> , <b>1988</b> , 46, 747-53   | 1.8  | 25  |
| 6 | SPECIFIC EX-VIVO DEPLETION OF HUMAN BONE MARROW T LYMPHOCYTES BY AN ANTI-PAN-T CELL (CD5) RICINA-CHAIN IMMUNOTOXIN. <i>Transplantation</i> , <b>1987</b> , 43, 491   | 1.8  | 6   |
| 5 | High sensitivity and specificity assay for detection of leukemia/lymphoma cells in human bone marrow. <i>Annals of the New York Academy of Sciences</i> , <b>1987</b> , 511, 473-82  | 6.5  | 3   |
| 4 | Cell-mediated immunity in children with chronic cholestasis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>1982</b> , 1, 385-8   | 2.8  | 14  |
| 3 | Eucharistic problems for celiac patients. <i>New England Journal of Medicine</i> , <b>1982</b> , 307, 898  | 59.2 | 7   |
| 2 | A CUP OF COFFEE FOR ALLERGIC RHINITIS. <i>Lancet, The</i> , <b>1982</b> , 319, 1133  | 4.0  |     |
| 1 | Hepatitis B and acute lymphoblastic leukemia. <i>Journal of Pediatrics</i> , <b>1982</b> , 101, 156-7  | 3.6  | 5   |